Influenza Drug Pipeline Analysis Report 2025

Influenza is a contagious respiratory illness caused by influenza viruses, affecting millions globally each year. It accounts for approximately one billion cases of seasonal influenza annually, including 3-5 million severe cases. There is a high unmet clinical need for better therapies to treat the disease, as current treatment options, such as antivirals, have limitations in efficacy and resistance. Furthermore, the growing focus on novel influenza drugs, next-generation antivirals, and monoclonal antibodies is likely to support pipeline growth in the coming years. Advancements in influenza therapeutics, including universal vaccines and innovative antiviral agents, are anticipated to accelerate research and development efforts.

Report Coverage

The Influenza Drug Pipeline Insight Report by the publisher gives comprehensive insights into influenza therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Influenza. The influenza report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The influenza pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with influenza treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to influenza.

Influenza Drug Pipeline Outlook

Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. It primarily spreads through respiratory droplets when an infected person coughs or sneezes. The virus can also survive on surfaces, facilitating transmission. Influenza occurs seasonally, with outbreaks typically taking place in colder months.

Influenza treatments focus on symptom relief and viral suppression. Antiviral medications like oseltamivir and zanamivir can reduce the severity and duration of symptoms. Vaccines, administered annually, remain the most effective preventive measure against the flu. Supportive care, including hydration and rest, is also recommended.

Influenza Epidemiology

Influenza remains a major global health concern, with around a billion cases annually, including 3-5 million severe illnesses. The CDC estimates between 9.3 million to 41 million flu cases annually in the United States, resulting in 120,000-710,000 hospitalizations and 6,300-52,000 deaths. A United Kingdom survey of 1,000 working-age adults highlighted the widespread impact of influenza during the 2018-2022 seasons.

Influenza - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of influenza drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• RNA-based Therapies
• Peptides
• Immunomodulators

By Route of Administration

• Oral
• Parenteral
• Others

Influenza Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total influenza clinical trials.

Influenza - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the influenza pipeline analysis include small molecules, monoclonal antibodies, RNA-based therapies, peptides, and immunomodulators. The influenza report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for influenza.

Influenza Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the influenza drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed influenza therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in influenza clinical trials:

• Hoffmann-La Roche
• Pfizer
• Sumitomo Pharma Co., Ltd.
• ModernaTX, Inc.
• Insight Therapeutics, LLC
• Cidara Therapeutics Inc.
• Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Arcturus Therapeutics, Inc.
• GlaxoSmithKline
• Novavax
• Sanofi
• Genentech, Inc.

Influenza Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for influenza. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of influenza drug candidates.

Drug: Ingavirin

Ingavirin® (60 mg capsules) is being evaluated in a Phase IV clinical study sponsored by Valenta Pharm JSC to assess its efficacy and safety in treating influenza and other acute respiratory viral infections in children aged 13 to 17. The study aims to examine its therapeutic benefits compared to a placebo. Expected to be completed by December 31, 2025, it will enroll approximately 80 participants.

Drug: Baloxavir Marboxil

Baloxavir Marboxil is being investigated in a Phase IIIb surveillance study sponsored by Hoffmann-La Roche to evaluate its pre-treatment and post-treatment susceptibility in children aged 1 to < 12 years with influenza. The study is expected to be completed by June 2027 and will enroll around 600 participants across multiple centers.

Drug: Zanamivir

Zanamivir (intravenous) is being evaluated in a Phase 2 study sponsored by GlaxoSmithKline (GSK) to assess its pharmacokinetics, safety, and tolerability in hospitalized neonates and infants under six months with complicated influenza infection. The study aims to determine the drug's effectiveness and safety profile in this vulnerable population. The clinical trial is expected to be completed by December 2026 and will enroll about 12 participants.

Reasons To Buy This Report

The Influenza Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for influenza. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into influenza collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Influenza - Pipeline Insight Report

• Which companies/institutions are leading the influenza drug development?
• What is the efficacy and safety profile of Influenza pipeline drugs?
• Which company is leading the influenza pipeline development activities?
• What is the current influenza commercial assessment?
• What are the opportunities and challenges present in the influenza drug pipeline landscape?
• What is the efficacy and safety profile of influenza pipeline drugs?
• Which company is conducting major trials for influenza drugs?
• Which companies/institutions are involved in influenza collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in influenza?

This product will be delivered within 3-5 business days.